Neochem Bio Solutions H1 FY27 Results Board Update

Board considers September 2026 financial results

Neochem Bio Solutions Limited informed the exchange that its board meeting on October 27, 2026 would consider and approve unaudited financial results for the half year ended September 30, 2026. The company subsequently submitted the unaudited half-yearly financial results to the exchange following the meeting. The disclosure marks the company’s first reported financial update for the first half of FY27. The source material does not provide the detailed revenue, profit, margin, or earnings per share figures for the September 2026 half year. Investors will therefore need to refer to the filed financial statements for the complete H1 FY27 performance data.

The board meeting intimation was issued for approval of results for the period ended September 30, 2026. Such meetings are a key disclosure event for listed companies because they formally place the latest financial performance before the board and the market. For Neochem Bio Solutions, the update follows a year in which it reported higher revenue and profitability for FY26. The September-half results will provide the next reported checkpoint on whether the operating progress seen in FY26 continued into FY27.

Trading window closure preceded the meeting

The company had closed its trading window from October 1, 2026 until 48 hours after the declaration of the H1 FY27 unaudited results. This was disclosed on September 28, 2026. The closure is intended to restrict trading by designated persons while unpublished price-sensitive information is being considered and finalised.

Neochem Bio Solutions also submitted a Regulation 74(5) demat confirmation certificate on October 8, 2026 for the quarter and half year ended September 30, 2026. That filing relates to confirmation of dematerialisation-related activity and is separate from the financial-results disclosure. Together, the announcements show the company completing routine listed-company compliance steps around the half-year closing process.

FY26 provides the immediate financial context

The company’s audited FY26 results, approved in May 2026, showed revenue from operations of ₹110.7 crore. This represented growth of more than 32% from the prior year. Total income for FY26 stood at ₹113.4 crore, also up 32% year on year, according to the company’s earnings-call presentation.

Profit after tax for FY26 was ₹12.0 crore, a 62% increase from the previous year. PAT margin improved to 10.6%, an expansion of 197 basis points. The company attributed the improvement to operating leverage and better profitability across its business. Its FY26 audited-results release also reported an unmodified opinion from statutory auditor Patel Mehta & Associates.

EBITDA and margin expansion in FY26

Neochem Bio Solutions reported FY26 EBITDA of ₹22.6 crore, up 53% year on year. EBITDA margin increased to 20.4% from 17.2% in the preceding year, an expansion of 321 basis points. The higher margin was reported alongside broad-based demand across the company’s product portfolio and end-user industries.

The company’s audited-results release presented EBITDA at ₹21.9 crore, compared with ₹14.8 crore in FY25, while the earnings-call presentation cited ₹22.6 crore. Both disclosures indicate a substantial year-on-year improvement in operating profit, although investors should use the audited financial statements for the final reported figure. Revenue from operations in the audited-results comparison was ₹110.69 crore for FY26 against ₹84.17 crore in FY25.

Second-half FY26 performance was stronger

For H2 FY26, revenue from operations was ₹64.9 crore, representing 37% growth over H2 FY25. EBITDA for the period was ₹12.6 crore, with an EBITDA margin of 19.4%. Profit after tax for the second half was ₹6.9 crore.

The H2 contribution indicates that a significant portion of FY26 revenue was generated in the latter half of the financial year. However, it does not establish a forecast for FY27. The unaudited September 2026 results are relevant because they will show the company’s reported performance during the first six months following that stronger second-half period.

Key reported FY26 financial metrics

Note: FY25 PAT of ₹7.4 crore is based on the audited-results comparison, while some historical summary data in the supplied material presents differing figures. The company’s audited filing remains the primary reference.

AGM approved FY26 accounts and reappointment

At its ninth annual general meeting on September 21, 2026, Neochem Bio Solutions’ shareholders approved the FY26 results. The company disclosed FY26 revenue of ₹110.7 crore and PAT of ₹12.0 crore in connection with the AGM. Shareholders also reappointed Dinesh Chopra, according to the exchange-related information provided.

The AGM approval followed the board’s May 18, 2026 approval of the audited financial results. The statutory auditors stated that the company had adequate internal financial controls over financial reporting and that these controls were operating effectively as of March 31, 2026. This forms part of the governance context for the subsequent H1 FY27 reporting cycle.

What the H1 FY27 filing means for investors

The filing confirms that Neochem Bio Solutions has completed the board-level approval process for unaudited results for the half year ended September 30, 2026. The detailed H1 numbers have not been included in the supplied information, so no conclusion can be made here on revenue growth, profitability, margin movement, or earnings for the period.

For investors, the main comparison point is FY26, when the company reported growth in revenue, EBITDA and profit after tax. The September 2026 financial statements will be important for assessing the company’s reported first-half operating performance against that base. Investors should also distinguish between unaudited half-yearly results and the audited full-year accounts released after the financial year closes.

Next disclosure to watch

Neochem Bio Solutions has stated that the unaudited half-yearly results for the period ended September 30, 2026 were submitted to the exchange after the October 27 board meeting. The next relevant information for the market will be the detailed financial statements and any accompanying management commentary or investor communication. Those disclosures can clarify the half-year revenue, expenses, operating profit, net profit and margins.

The immediate takeaway is procedural but relevant: the board has considered the September 2026 results, and the company has completed the related exchange submission. FY26 established a base of ₹110.7 crore in revenue and ₹12.0 crore in PAT. The detailed H1 FY27 filing will show how the business performed during the next reported period.